JP2022510041A5 - - Google Patents
Info
- Publication number
- JP2022510041A5 JP2022510041A5 JP2021553755A JP2021553755A JP2022510041A5 JP 2022510041 A5 JP2022510041 A5 JP 2022510041A5 JP 2021553755 A JP2021553755 A JP 2021553755A JP 2021553755 A JP2021553755 A JP 2021553755A JP 2022510041 A5 JP2022510041 A5 JP 2022510041A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- oligonucleotide
- nucleic acid
- sequence
- spinocerebellar ataxia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774791P | 2018-12-03 | 2018-12-03 | |
| US62/774,791 | 2018-12-03 | ||
| US201962877142P | 2019-07-22 | 2019-07-22 | |
| US62/877,142 | 2019-07-22 | ||
| PCT/US2019/064054 WO2020117702A1 (en) | 2018-12-03 | 2019-12-02 | Methods for the treatment of trinucleotide repeat expansion disorders associated with msh3 activity |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022510041A JP2022510041A (ja) | 2022-01-25 |
| JP2022510041A5 true JP2022510041A5 (https=) | 2022-12-09 |
| JP7714162B2 JP7714162B2 (ja) | 2025-07-29 |
| JP7714162B6 JP7714162B6 (ja) | 2025-09-08 |
Family
ID=70974779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553755A Active JP7714162B6 (ja) | 2018-12-03 | 2019-12-02 | Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220072028A1 (https=) |
| JP (1) | JP7714162B6 (https=) |
| KR (1) | KR20210099090A (https=) |
| AU (1) | AU2019394847A1 (https=) |
| CA (1) | CA3121779A1 (https=) |
| MX (1) | MX2021006463A (https=) |
| WO (2) | WO2020117702A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210355491A1 (en) * | 2020-04-20 | 2021-11-18 | University Of Massachusetts | Oligonucleotides for msh3 modulation |
| US20230313185A1 (en) * | 2020-05-08 | 2023-10-05 | Triplet Therapeutics, Inc. | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |
| AR122534A1 (es) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
| EP4247392A4 (en) * | 2020-06-03 | 2025-10-08 | Takeda Pharmaceuticals Usa Inc | METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY |
| WO2021252799A2 (en) * | 2020-06-11 | 2021-12-16 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing msh3 expression |
| US20240263179A1 (en) * | 2021-06-04 | 2024-08-08 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |
| WO2023168304A2 (en) * | 2022-03-02 | 2023-09-07 | Triplet Therapeutics, Inc. | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |
| WO2024251211A1 (en) * | 2023-06-06 | 2024-12-12 | Revir Therapeutics, Inc. | Compositions, methods, and systems for modulating splicing of msh3 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999010369A1 (en) * | 1997-08-28 | 1999-03-04 | Thomas Jefferson University | Compositions, kits, and methods for effecting adenine nucleotide modulation of dna mismatch recognition proteins |
| US20050244851A1 (en) * | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| WO2008157747A1 (en) * | 2007-06-21 | 2008-12-24 | The Jackson Laboratory | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders |
| US10202599B2 (en) * | 2011-08-11 | 2019-02-12 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| WO2015171918A2 (en) * | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
| EP4464338A3 (en) * | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| EP3806850A2 (en) * | 2018-06-15 | 2021-04-21 | Ideaya Biosciences, Inc. | Methods of inhibiting proliferative cells |
| AR122534A1 (es) * | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
| US20240263179A1 (en) * | 2021-06-04 | 2024-08-08 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |
-
2019
- 2019-12-02 JP JP2021553755A patent/JP7714162B6/ja active Active
- 2019-12-02 MX MX2021006463A patent/MX2021006463A/es unknown
- 2019-12-02 CA CA3121779A patent/CA3121779A1/en active Pending
- 2019-12-02 AU AU2019394847A patent/AU2019394847A1/en active Pending
- 2019-12-02 KR KR1020217020797A patent/KR20210099090A/ko active Pending
- 2019-12-02 US US17/299,186 patent/US20220072028A1/en active Pending
- 2019-12-02 WO PCT/US2019/064054 patent/WO2020117702A1/en not_active Ceased
- 2019-12-02 WO PCT/US2019/064055 patent/WO2020117703A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022510041A5 (https=) | ||
| CA2071510C (en) | 2' modified oligonucleotides | |
| EP1544297A3 (en) | Medicament for treatment of Duchenne muscular dystrophy | |
| JP2005520489A5 (https=) | ||
| US5849900A (en) | Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids | |
| BRPI0811170B8 (pt) | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila | |
| JP2004509619A5 (https=) | ||
| JP2019534009A5 (https=) | ||
| JPH07503856A (ja) | プロテインキナーゼｃのオリゴヌクレオチド調節 | |
| WO1994007367A9 (en) | Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids | |
| TW201202418A (en) | Treatment of Methionine Sulfoxide Reductase A (MSRA) related diseases by inhibition of natural antisense transcript to MSRA | |
| JP2021505129A5 (https=) | ||
| CA3241870A1 (en) | Splice switcher antisense oligonucleotides with modified backbone chemistries | |
| JP2006502243A5 (https=) | ||
| JP2024522147A5 (https=) | ||
| JP2004507272A (ja) | アラビノフラノース類似体およびデオキシリボースヌクレオチドのキメラアンチセンス | |
| JP2021510512A5 (https=) | ||
| JP2007530431A5 (https=) | ||
| JP2004503232A5 (https=) | ||
| US20250376684A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| AU2018421460B2 (en) | Therapeutic uses and methods | |
| US20240336920A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JP2022514648A (ja) | Ｃａｒｄ９を標的とするアンチセンスオリゴヌクレオチド | |
| WO2020038973A1 (en) | Antisense oligonucleotides targeting sptlc1 | |
| JPWO2023171587A5 (https=) |